Research programme: neuroprotective therapies - Endo Pharmaceuticals

Drug Profile

Research programme: neuroprotective therapies - Endo Pharmaceuticals

Alternative Names: ADNF-9; AL-209; AL-309; AL-408; AL-508; SAL; SALLRSIPA

Latest Information Update: 06 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allon Therapeutics
  • Developer Endo International
  • Class Nerve growth factors; Neuropeptides
  • Mechanism of Action Neuron stimulants; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Preclinical Alzheimer's disease; Fetal alcohol syndrome; Neurodegenerative disorders; Peripheral nervous system diseases
  • No development reported Eye disorders

Most Recent Events

  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 16 Jul 2013 Allon Therapeutics has been acquired by Paladin Labs
  • 29 Sep 2011 No development reported - Preclinical for Eye disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top